We demonstrated that ICV injection of [Ala11, D-Leu15]-orexin-B (AL-OXB), a selective and potent OX2R agonist [21], suppresses fragmentation of wakefulness as well as cataplexy-like episodes without in-vivo OX1R activation in orexin knockout (OXKO) mice. Here, HCRT is linked to Cataplexy.